- Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order
- Anesthesiologists’ Group Urges Limits on Ketamine Use
- ‘E-reporting’ Daily Symptoms Boosts Cancer Patients’ Well-Being
- Weight-Obsessed Teens Face Triple the Odds for Self-Harm
- Wrong Smartphone Settings Can Lead to Missed Alerts From Linked Diabetes Devices
- CDC: U.S. Influenza Activity in the United States Remains Elevated
- Federal Judge Halts NIH Cuts That Could Impact Medical Research
- GLP-1 Meds Can Work Wonders for Kidney Health
- Shark Attacks Plummeted Worldwide Last Year
- Most Americans Keep Chronic Health Conditions Hidden at Work: Poll
Antiviral Combination Approved for Hepatitis C

Viekira Pak, a combination of four antiviral drugs — ombitasvir, paritaprevir, ritonavir and dasabuvir — has been approved by the U.S. Food and Drug Administration to treat hepatitis C infection, including a major complication, cirrhosis of the liver.
Some 3.2 million Americans are infected with the viral disease, which can lead to complications including reduced liver function, liver failure or liver cancer, the FDA said in a news release. Most infected people have no symptoms before onset of liver damage.
Without proper treatment, 15 percent to 30 percent will develop advanced liver disease known as cirrhosis, the agency said.
The combination pack’s safety and effectiveness were evaluated in clinical studies involving more than 2,300 people with chronic hepatitis C, with and without cirrhosis. The most common side effects included fatigue, itching, weakness, lack of energy, nausea and trouble sleeping.
Viekira Pak is marketed by AbbVie Inc., based in North Chicago.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.